Interstitial Lung Disease Pipeline Analysis, 2024: Clinical Trials, FDA, EMA, and PMDA Approvals, Emerging Therapies, and Growth Prospects

DelveInsight's, "Interstitial Lung Diseases Pipeline Insight 2024" report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in the Interstitial Lung Disease pipeline landscape. It covers the Interstitial Lung Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Interstitial Lung Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Interstitial Lung Disease Pipeline Report
• DelveInsight's interstitial lung disease Pipeline report depicts a robust space with 120+ active players working to develop 120 + pipeline therapies for interstitial lung disease treatment.
• The leading Interstitial Lung Disease Companies working in the market include Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, Bristol-Myers Squibb, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, PureTech Health, Novartis, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Lung Therapeutics, AdAlta, Ark Biosciences, and others.
• Promising Interstitial Lung Disease Therapies in the various stages of development include AD-214, Abatacept, ATYR1923, Pirfenidone inhalation, RO-0220912, Lung stem cells, Bardoxolone methyl, Pamrevlumab, Deupirfenidone, INOpulse, OATD 01, LT 0011, GDC 3280, Blade Therapeutics, BI 1015550, PRA 023, Yifenidone, Riociguat, Treprostinil Palmitil, BMS 986278, Pirfenidone inhalation, Deupirfenidone, Zinpentraxin alfa, AK 3280, Ianalumab, LTI-03, HZN-825, Tipelukast, ENV-101, PLN-74809, KD025, Setanaxib, TAS-115,Axatilimab, MG-S-2525, GB0139,CSL312 and Saracatinib, others.
• May 2024: Columbia University- Radiology is an important component of the multidisciplinary team. The primary goal of this project will be to create a tool using findings on chest computed tomography (CT) for nearly 300 patients with the most common types of fibrosis. The tool will be tested using chest CT scans of an additional 100 patients with the 3 most common diagnoses of fibrosis. The second objective will be to further validate the tool by performing a reader study with 3 co-investigating radiologists and ask them to look at 100 CT scans of patients with fibrosis without tool and then with tool and see if accuracy of diagnosis improves compared to the working diagnosis when using the tool.
• April 2024:- Dr. Denis O'Donnell- The purpose of this study is to evaluate the acute effects of inhaled therapy (fentanyl citrate) on breathing discomfort (dyspnea) in individuals with mild-to-moderate ILD, as well as examine the potential mechanisms of dyspnea relief. Patients with interstitial lung disease (ILD) experience distressing activity-related respiratory discomfort which is challenging to manage therapeutically. Interventions such as pulmonary rehabilitation, collaborative self-management, supplemental oxygen therapy and oral medications, are variably effective and therapeutic responses to each in individual patients are difficult to predict.

Request a sample and discover the recent advances in Glioma @ Glioma Pipeline Outlook Report- https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Interstitial Lung Disease Overview
Interstitial lung disease (diffused parenchymal diseases) are a heterogeneous group of disorders characterized by fibrosis (scarring) of the lungs. These are classified on the basis of histopathological, radiologic and clinical parameters. The classification system used to describe interstitial lung disease categorizes conditions based on clinical, histopathological or radiologic parameters. Clinical classification groups ILD by its causes to help differentiate exogenous or endogenous factors.

Interstitial Lung Disease Emerging Drugs Profile
• DWN12088: Daewoong Pharmaceutical
• LYT-100: PureTech
• BMS-986278: Bristol-Myers Squibb

Learn more about Interstitial Lung Disease in clinical trials @ Interstitial Lung Disease Drugs- https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Interstitial Lung Disease Therapeutics Assessment
There are approx. 120+ Interstitial Lung Disease companies which are developing the Interstitial Lung Disease therapies. The Interstitial Lung Disease companies which have their Interstitial Lung Disease drug candidates in the most advanced stage, i.e phase III include Pfizer.

DelveInsight's Interstitial Lung Disease Pipeline report covers around 120+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Discover more about Interstitial Lung Disease in development @ Interstitial Lung Disease Clinical Trials- https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Interstitial Lung Disease Companies
Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, Bristol-Myers Squibb, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, PureTech Health, Novartis, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Lung Therapeutics, AdAlta, Ark Biosciences, and others.

Interstitial Lung Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous

Interstitial Lung Disease Products have been categorized under various Molecule types such as
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

To learn more about Interstitial Lung Disease, visit @ Interstitial Lung Disease Segmentation- https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Interstitial Lung Disease Pipeline Report
• Coverage- Global
• Interstitial Lung Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Interstitial Lung Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Interstitial Lung Disease Therapeutic Companies- Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, Bristol-Myers Squibb, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, PureTech Health, Novartis, Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Lung Therapeutics, AdAlta, Ark Biosciences, and others
• Interstitial Lung Disease Therapies- AD-214, Abatacept, ATYR1923, Pirfenidone inhalation, RO-0220912, Lung stem cells, Bardoxolone methyl, Pamrevlumab, Deupirfenidone, INOpulse, OATD 01, LT 0011, GDC 3280, Blade Therapeutics, BI 1015550, PRA 023, Yifenidone, Riociguat, Treprostinil Palmitil, BMS 986278, Pirfenidone inhalation, Deupirfenidone, Zinpentraxin alfa, AK 3280, Ianalumab, LTI-03, HZN-825, Tipelukast, ENV-101, PLN-74809, KD025, Setanaxib, TAS-115,Axatilimab, MG-S-2525, GB0139,CSL312 and Saracatinib, others.

For further information on the Interstitial Lung Disease Pipeline Therapeutics, reach out @ Interstitial Lung Disease Products Development- https://www.delveinsight.com/sample-request/interstitial-lung-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Interstitial Lung Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Interstitial Lung Disease- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. RO-0220912: Roche
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Daratumumab: Janssen Biotech
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. BGB 16673: BeiGene
15. Drug profiles in the detailed report…..
16. Preclinical Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Interstitial Lung Disease Key Companies
21. Interstitial Lung Disease Key Products
22. Interstitial Lung Disease- Unmet Needs
23. Interstitial Lung Disease- Market Drivers and Barriers
24. Interstitial Lung Disease- Future Perspectives and Conclusion
25. Interstitial Lung Disease Analyst Views
26. Interstitial Lung Disease Key Companies
27. Appendix

List of Other Important Links-

Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
Vulvar Cancer Market- https://www.delveinsight.com/report-store/vulvar-cancer-market
Vascular Grafts Market- https://www.delveinsight.com/report-store/vascular-grafts-market
Acne Vulgaris Market- https://www.delveinsight.com/report-store/acne-vulgaris-av-market
Bone Growth Stimulator Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Angiofibroma Market- https://www.delveinsight.com/report-store/angiofibroma-market
Atopic Dermatitis Market- https://www.delveinsight.com/report-store/atopic-dermatitis-market
Sepsis Market- https://www.delveinsight.com/report-store/sepsis-market
Tendonitis Market- https://www.delveinsight.com/report-store/tendonitis-market
Fabry Disease Market- https://www.delveinsight.com/report-store/fabry-disease-market
Ascites Market- https://www.delveinsight.com/report-store/ascites-market
Systemic Lupus Erythematosus Market- https://www.delveinsight.com/report-store/systemic-lupus-erythematosus-market
Post Operative Pain Management Market- https://www.delveinsight.com/report-store/post-operative-pain-management-market
Cxcr Inhibitors Market- https://www.delveinsight.com/report-store/c-x-c-chemokine-receptor-inhibitors-competitive-landscape-market-and-pipeline-analysis
Androgen Receptor Inhibitor Market- https://www.delveinsight.com/report-store/androgen-receptor-inhibitor-market-forecast
Antibody Drug Conjugate Market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
STS Devices Market- https://www.delveinsight.com/report-store/sts-devices-market
Positive Airway Pressure Device Market- https://www.delveinsight.com/report-store/positive-airway-pressure-device-market

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.